



Express Mail No. EL 477 035 815 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Robert E. Klem

Application No.: 10/053,645

Group Art Unit: 1642

Filed: January 22, 2002

Examiner: To Be Assigned

For: METHODS AND COMPOSITIONS FOR
TREATING A CELL-PROLIFERATIVE
DISORDER USING CRE DECOY
OLIGOMERS, BCL-2 ANTISENSE
OLIGOMERS, AND HYBRID
OLIGOMERS THEREOF

Attorney Docket No.: 10412-022

Confirmation No.: 3607

REQUEST TO CORRECT PRIORITY CLAIM UNDER 35 U.S.C. § 120(e)(1)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant respectfully requests that the claim for priority be corrected under 35 U.S.C. § 120(e)(1) for the reasons set forth below. The above-identified application is intended to claim priority to provisional application No. 60/263,244, filed January 22, 2001. However, due to a typographical error, the data set forth in the transmittal papers filed on January 22, 2002 inadvertently claimed priority to "application no. 60/283,244 filed on January 22, 2001." Please amend the priority claim of the above-identified application by deleting reference to "60/283,244" and inserting therefor -- "60/263,244" --. Applicant submits concurrently herewith a Request for Corrected Filing Receipt in order to correct the priority data.

Please make the appropriate correction in the record of the above-identified application. Applicant believes that no fee is required in connection. However, if a fee is required, please charge the fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

A duplicate of this sheet is enclosed.

Date April 15, 2002


Respectfully submitted,

by *Jaqueline Benn*
Laura A. Coruzzi Reg. No. 43,492
30,742

Laura A. Coruzzi

(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, N.Y. 10036-2711
(212) 790-9090



4-17-02

Receipt
#3

Express Mail No. EL 477 035 815 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Robert E. Klem

Application No.: 10/053,645

Group Art Unit: 1642

Filed: January 22, 2002

Examiner: To Be Assigned

For: METHODS AND COMPOSITIONS FOR
TREATING A CELL-PROLIFERATIVE
DISORDER USING CRE DECOY
OLIGOMERS, BCL-2 ANTISENSE
OLIGOMERS, AND HYBRID
OLIGOMERS THEREOF

Attorney Docket No.: 10412-022

Confirmation No.: 3607

REQUEST FOR CORRECTION OF FILING RECEIPT

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Sir:

Applicant encloses herewith the original Filing Receipt and a copy thereof indicating in red ink the necessary correction in connection with the above-identified application. Specifically, the domestic priority data as claimed by applicant is incorrect due to a typographical error on the part of the Applicant. Please correct the domestic priority data as claimed by applicant by deleting reference to "60/283,244 04/11/2001" and inserting therefor -- 60/263,244 01/22/2001" --.

Applicant submits concurrently herewith a Request to Correct Priority Claim Under 35 U.S.C. § 120(e)(I) and a copy is attached as Exhibit A.

Please make the appropriate correction and issue a Corrected Filing Receipt.

Applicant believes that no fee is required in connection with this request. However, if a fee is required, please charge the fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

A duplicate of this sheet is enclosed.

Date April 15, 2002

Respectfully submitted,

by: *Jacqueline Benn*
Laura A. Coruzzi

Reg No. *43,492*
30,742

Laura A. Coruzzi

(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, N.Y. 10036-2711
(212) 790-9090

Enclosure



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/053,645	01/22/2002	1642	997	10412-022		71	7

20583
PENNIE AND EDMONDS
1155 AVENUE OF THE AMERICAS
NEW YORK, NY 100362711

CONFIRMATION NO. 3607

FILING RECEIPT



OC000000007705002

Date Mailed: 03/25/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Robert E. Klem, Berkeley, NJ;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/283,244 04/11/2001 ✓

(*) Data inconsistent with PTO records.

Foreign Applications

If Required, Foreign Filing License Granted 03/22/2002

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No


** SMALL ENTITY **

Title

Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof

Preliminary Class

435



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).